Skip to main content

27.07.2020 | COVID-19 | Hot Topics in Atherosclerosis (A Gotto, Section Editor) | Ausgabe 9/2020 Zur Zeit gratis

Current Atherosclerosis Reports 9/2020

Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis

Current Atherosclerosis Reports > Ausgabe 9/2020
Patrick M. Moriarty, Lauryn K. Gorby, Erik S. Stroes, John P. Kastelein, Michael Davidson, Sotirios Tsimikas
Wichtige Hinweise
This article is part of the Topical Collection on Hot Topics in Atherosclerosis

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Purpose of Review

The COVID-19 pandemic has infected over > 11 million as of today people worldwide and is associated with significant cardiovascular manifestations, particularly in subjects with preexisting comorbidities and cardiovascular risk factors. Recently, a predisposition for arterial and venous thromboses has been reported in COVID-19 infection. We hypothesize that besides conventional risk factors, subjects with elevated lipoprotein(a) (Lp(a)) may have a particularly high risk of developing cardiovascular complications.

Recent Findings

The Lp(a) molecule has the propensity for inhibiting endogenous fibrinolysis through its apolipoprotein(a) component and for enhancing proinflammatory effects such as through its content of oxidized phospholipids. The LPA gene contains an interleukin-6 (IL-6) response element that may induce an acute phase–type increase in Lp(a) levels following a cytokine storm from COVID-19.


Thus, subjects with either baseline elevated Lp(a) or those who have an increase following COVID-19 infection, or both, may be at very high risk of developing thromboses. Elevated Lp(a) may also lead to acute destabilization of preexisting but quiescent atherosclerotic plaques, which might induce acute myocardial infarction and stroke. Ongoing studies with IL-6 antagonists may be informative in understanding this relationship, and registries are being initiated to measure Lp(a) in subjects infected with COVID-19. If indeed an association is suggestive of being causal, consideration can be given to systematic testing of Lp(a) and prophylactic systemic anticoagulation in infected inpatients. Therapeutic lipid apheresis and pharmacotherapy for the reduction of Lp(a) levels may minimize thrombogenic potential and proinflammatory effects. We propose studies to test the hypothesis that Lp(a) may contribute to cardiovascular complications of COVID-19.

Nutzen Sie Ihre Chance: Dieser Inhalt ist zurzeit gratis verfügbar.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Unsere Produktempfehlungen

e.Med Interdisziplinär


Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Über diesen Artikel

Weitere Artikel der Ausgabe 9/2020

Current Atherosclerosis Reports 9/2020 Zur Ausgabe

Statin Drugs (R. Ceska, Section Editor)

The Role of Statins in Current Guidelines

Women and Ischemic Heart Disease (P. Kohli, Section Editor)

Spontaneous Coronary Artery Dissection: Latest Developments and New Frontiers

Evidence-Based Medicine, Clinical Trials and Their Interpretations (L. Roever,Section Editor)

Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis

Coronary Heart Disease (S. Virani and S. Naderi, Section Editor)

Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?

Coronavirus Corona-Update

Die aktuelle Entwicklung im Überblick: Nachrichten, Webinare, Übersichtsarbeiten.